SARS-CoV-2 evades natural killer cell cytotoxic responses

In a recent study posted to the bioRxiv* preprint server, researchers at Stanford University School of Medicine revealed the mechanism via severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) escapes natural killer (NK) cell cytotoxic reactions.

Background

The immune reaction to viral infection is influenced significantly by NK cells, which are innate lymphocytes. These cytotoxic effector cells react quickly to viral infection via addressing and lysing infected cells. 

Studies evaluating the immune reaction in CoV disease 2019 (COVID-19) during the SARS-CoV-2 pandemic have found that NK cells are less prevalent in the peripheral blood of severe SARS-CoV-2 patients versus healthy donors. In addition, immune profiling has revealed substantial, severity-related transcriptional and phenotypic alterations in the peripheral NK cells that persist in SARS-CoV-2 patients' blood.

Though multiple studies have shown NK cells can inhibit SARS-CoV-2 replication in vitro, the mechanism via which NK cells react immediately to SARS-CoV-2-infected cells remains uncertain. This is especially crucial because several viruses adopt techniques to avoid being detected and eliminated by NK cells.

Study: SARS-CoV-2 escapes direct NK cell killing through Nsp1-mediated downregulation of ligands for NKG2DStudy: SARS-CoV-2 escapes direct NK cell killing through Nsp1-mediated downregulation of ligands for NKG2D

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

About the study

The present research aimed to assess the capacity of SARS-CoV-2 to adjust NK cell identification and lysis of virus-infected cells. The team developed an in vitro model approach that analyzes the NK cell reaction to SARS-CoV-2-infected cells using primary NK cells derived from healthy donors and replication-competent SARS-CoV-2. To further elucidate how the balance between SARS-CoV-2 detection and escape leads to COVID-19, they concentrated on examining the direct killing of SARS-CoV-2-infected target cells by the NK cells.

Adenocarcinomic human alveolar basal epithelial (A549)-angiotensin-converting enzyme 2 (ACE2) cells, identified and lysed by NK cells and are SARS-CoV-2 infectible, were used as a model by the authors to study the NK cell reaction to COVID-19. They introduced NK cells obtained from healthy donors preactivated overnight with interleukin 2 (IL-2) to address cells infected with SARS-CoV-2 for 48 hours to comprehend how exposure to SARS-CoV-2-infected target cells affects NK cell activity and phenotype.

The researcher evaluated whether SARS-CoV-2 modifies NK cells' capacity to annihilate infected target cells. Further, they explored how SARS-CoV-2-infected cells managed to escape being lysed and recognized by NK cells.

The authors examined NK group 2D-ligand (NKG2D-L) expression on the cells that persisted after being co-cultured with NK cells to investigate the relationship between NKG2D-L expression and the killing of SARS-CoV-2-infected cells. The team then tried to figure out how SARS-CoV-2 affects NKG2D-L protein expression across SARS-CoV-2-infected cells.

NK cells respond similarly to SARS-CoV-2-infected and mock-infected target cells. A) Representative flow plots (left) and boxplot (right) showing the percentage of mNeonGreen-positive A549-ACE2 cells following infection with either mNeon Green SARS-CoV-2 (MOI 0.5) or media (“mock”) at an MOI of 0.5 for either 24 or 48 hours. Bar plots representNK cells respond similarly to SARS-CoV-2-infected and mock-infected target cells. A) Representative flow plots (left) and boxplot (right) showing the percentage of mNeonGreen-positive A549-ACE2 cells following infection with either mNeon Green SARS-CoV-2 (MOI 0.5) or media (“mock”) at an MOI of 0.5 for either 24 or 48 hours. Bar plots represent n=4 technical replicates ∓ SD values. B) Schematic illustrating the experimental design of NK cell killing assays. C-D) Plots showing the median fluorescence intensity (C) and % of NK cells positive (D) for eight different NK cell markers by flow cytometry upon culture with no targets, mock-infected targets, or SARS-CoV-2-infected targets. E-F) Representative flow plots (E) and quantitations (F) of percentage of NK cells expressing CD107a and IFNγ upon culture with no targets, mock-infected targets, or SARS-CoV-2-infected targets. Significance values were determined using a paired Wilcoxon ranked-sum test with the Bonferroni correction for multiple hypothesis testing.

Results

Overall, the study results depicted that NK cells have weak cytotoxic reactions towards SARS-CoV-2-infected targets, selectively killing non-infected bystander cells. Furthermore, the team showed that the SARS-CoV-2-infected cells' significant downregulation of ligands for the stimulating NKG2D receptor was what caused this escape from NK cell-mediated killing.

Indeed, NK cells may efficiently identify and kill infected cells in the early phases of SARS-CoV-2 infection before NKG2D-L downregulation. Nevertheless, the NK cells lose this ability following the expression of viral proteins inside infected cells. The current data show that, when introduced to the culture at later timestamps following SARS-CoV-2 infection, post-expression of viral proteins that dampen the innate immune response, NK cells cannot kill infected cells effectively. Since a small window exists for the elimination of the infected cells before bystander cell killing might occur, the investigators noted that the timing of NK cell migration to the infection site could be crucial in deciding whether NK cells were pathogenic or protective in COVID-19.

Finally, the authors discovered that SARS-CoV-2 non-structural protein 1 (Nsp1) causes the downregulation of NKG2D-L. They also illustrated that transfection with just Nsp1 was enough to impart tolerance to NK cell killing. This observation has crucial implications for NK cell-facilitated regulation of SARS-CoV-2 since the preferred evasion of infected cells with the killing of bystander cells might lead to SARS-CoV-2 pathogenesis.

Conclusions

Collectively, the current investigation deeply examines the NK cell reaction to SARS-CoV-2 and offers new information about the function of NK cells in COVID-19. The researchers discovered that SARS-CoV-2-infected cells evade being destroyed by healthy NK cells in a cell-intrinsic way, leading to the preferential destruction of non-infected bystander cells. The capability of infected cells to escape NK cell identification needs infection to last long enough to facilitate an infected cell to exhibit SARS-CoV-2 encoded proteins. Besides, the present results highlight the significance of studying the temporal dynamics of the NK cell reaction to SARS-CoV-2-infected cells.

Additionally, the team showed that the downregulation of NKG2D-L drives the process of NK cell recognition evasion of SARS-CoV-2. The primary characteristic in the NK cell response to SARS-CoV-2, according to the findings, was the loss of NKG2D-L. The study data further demonstrated that the SARS-CoV-2 Nsp1 protein was responsible for this ligand downregulation and that Nsp1 itself was adequate to induce direct NK cell escape. The current work depicted that NK cell responses to SARS-CoV-2-infected cells might be partially or fully rescued by reducing the activity of Nsp1, proving that this protein was an even more desirable target than previously believed.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 13 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Shanet Susan Alex

Written by

Shanet Susan Alex

Shanet Susan Alex, a medical writer, based in Kerala, India, is a Doctor of Pharmacy graduate from Kerala University of Health Sciences. Her academic background is in clinical pharmacy and research, and she is passionate about medical writing. Shanet has published papers in the International Journal of Medical Science and Current Research (IJMSCR), the International Journal of Pharmacy (IJP), and the International Journal of Medical Science and Applied Research (IJMSAR). Apart from work, she enjoys listening to music and watching movies.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Susan Alex, Shanet. (2023, May 13). SARS-CoV-2 evades natural killer cell cytotoxic responses. News-Medical. Retrieved on November 24, 2024 from https://www.news-medical.net/news/20220622/SARS-CoV-2-evades-natural-killer-cell-cytotoxic-responses.aspx.

  • MLA

    Susan Alex, Shanet. "SARS-CoV-2 evades natural killer cell cytotoxic responses". News-Medical. 24 November 2024. <https://www.news-medical.net/news/20220622/SARS-CoV-2-evades-natural-killer-cell-cytotoxic-responses.aspx>.

  • Chicago

    Susan Alex, Shanet. "SARS-CoV-2 evades natural killer cell cytotoxic responses". News-Medical. https://www.news-medical.net/news/20220622/SARS-CoV-2-evades-natural-killer-cell-cytotoxic-responses.aspx. (accessed November 24, 2024).

  • Harvard

    Susan Alex, Shanet. 2023. SARS-CoV-2 evades natural killer cell cytotoxic responses. News-Medical, viewed 24 November 2024, https://www.news-medical.net/news/20220622/SARS-CoV-2-evades-natural-killer-cell-cytotoxic-responses.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics